Search clinical trials for: SAR444245

Total 7 results

M.D. Anderson Cancer Center
Sanofi

Withdrawn

Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

Head and Neck Cancer | Oropharynx Cancer | Squamous Cell Carcinoma

United States
Sanofi

Completed

First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects

Overweight | Healthy Subjects

United States
Sanofi
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

Squamous Cell Carcinoma of Head and Neck

Spain, Italy, United States, Chile, France, Argentina, Canada, Germany, Korea, Republic of, Netherlands, Taiwan
Sanofi

Recruiting

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

Neoplasm

United States, Canada, China, Korea, Republic of, Singapore
Chiba University

Completed

Ifenprodil Tartrate Treatment of Adolescents With Post-traumatic Stress Disorder: a Double-blind, Placebo-controlled Trial

Posttraumatic Stress Disorders

Japan
Synthorx, Inc, a Sanofi company

Recruiting

A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) (HAMMER)

Metastasis

United States, Australia, Singapore, Spain, Argentina, Chile
Sanofi

Recruiting

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Plasma Cell Myeloma Refractory

France, Australia, Greece, Italy, Norway, United States, Portugal, Puerto Rico

3

Subscribe